Ocera Therapeutics, Inc. (OCRX) Downgraded to Sell at Zacks Investment Research
Zacks Investment Research downgraded shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) from a hold rating to a sell rating in a research note released on Wednesday, May 17th.
According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “
A number of other analysts have also recently commented on the company. HC Wainwright reiterated a buy rating and set a $4.00 price objective on shares of Ocera Therapeutics in a research report on Wednesday, May 10th. Aegis reiterated a buy rating and set a $3.00 price objective on shares of Ocera Therapeutics in a research report on Monday, April 17th. JMP Securities cut Ocera Therapeutics from an outperform rating to a market perform rating in a report on Tuesday, January 31st. Finally, Stifel Nicolaus cut Ocera Therapeutics from a buy rating to a hold rating and set a $1.00 price target for the company. in a report on Monday, January 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $3.90.
Shares of Ocera Therapeutics (OCRX) traded down 1.03% on Wednesday, hitting $0.96. 327,065 shares of the stock traded hands. The firm’s 50 day moving average is $1.13 and its 200-day moving average is $1.39. The company’s market cap is $25.45 million. Ocera Therapeutics has a 12 month low of $0.52 and a 12 month high of $3.15.
Ocera Therapeutics (NASDAQ:OCRX) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.04. Ocera Therapeutics had a negative return on equity of 148.87% and a negative net margin of 4,416.26%. Equities analysts predict that Ocera Therapeutics will post ($1.10) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Ocera Therapeutics, Inc. (OCRX) Downgraded to Sell at Zacks Investment Research” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/06/16/ocera-therapeutics-inc-ocrx-downgraded-by-zacks-investment-research-to-sell-updated-updated-updated.html.
Several institutional investors have recently added to or reduced their stakes in OCRX. Great Point Partners LLC purchased a new position in Ocera Therapeutics during the third quarter valued at $5,184,000. VHCP Management LLC raised its position in Ocera Therapeutics by 7.5% in the third quarter. VHCP Management LLC now owns 856,550 shares of the biopharmaceutical company’s stock valued at $2,261,000 after buying an additional 60,000 shares in the last quarter. VHCP Management II LLC raised its position in Ocera Therapeutics by 14.8% in the third quarter. VHCP Management II LLC now owns 1,088,372 shares of the biopharmaceutical company’s stock valued at $2,873,000 after buying an additional 140,000 shares in the last quarter. Interwest Venture Management Co. purchased a new position in Ocera Therapeutics during the fourth quarter valued at $2,621,000. Finally, Renaissance Technologies LLC raised its position in Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 33,300 shares in the last quarter. 24.35% of the stock is currently owned by institutional investors and hedge funds.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.